PureTech Health Celebrates FDA Approval of Cobenfy: A Milestone in Schizophrenia Treatment
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has achieved a significant milestone with the FDA's recent approval of Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in adults.
FDA Approves KarXT To Treat Schizophrenia; PureTech Health Gets $29 Mln Milestone Payment
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb (BMS) in March of 2024. Royalty Pharma had acquired an interest in PureTech's royalty in KarXT.
PureActiv will deploy across multiple locations to detect unauthorized access as ships travel through the waterway system.
PureTech Systems Inc., the leader in geospatial AI-boosted video analytics for wide-area perimeter and border security, is ...
PureTech also argues the device has a favourable safety profile, as its active ingredients do not enter the bloodstream, thereby giving it a safety profile similar to placebo.
The PureActiv enhancement automatically validates access control security violations and dismisses nuisance alarms.
PureTech Health (PRTC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on August 28. Analyst Thomas Smith from Leerink Partners reiterated a Buy rating ...
Christine Lagarde is under pressure to ramp up the pace of interest rate cuts in the eurozone after French and Spanish ...
Company car drivers will face a 32% benefit-in-kind (BiK) tax charge for the DS 4 PureTech, owing to its CO2 emissions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback